ACYW135X meningococcal conjugate vaccine - Sinovac Biotech
Alternative Names: ACYW 135X meningococcal conjugate vaccine - Sinovac Biotech; Meningococcal vaccine groups A,C,W-135, Y, X conjugate - Sinovac BiotechLatest Information Update: 07 Apr 2026
At a glance
- Originator Sinovac Biotech
- Class Conjugate vaccines; Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Meningococcal infections
Most Recent Events
- 22 Mar 2026 Sinovac Biotech plans a phase III trial for Meningococcal infections (In children) (Parenteral) (NCT07505888)
- 22 Mar 2026 Sinovac Biotech plans a phase III trial for Meningococcal infections (Prevention, In infants) at an unknown location in March 2026 (NCT07505836)
- 22 Mar 2026 Sinovac Biotech plans a phase III trial for Meningococcal infections (Prevention, In infants), in March 2026 (NCT07505810)